SRZN
Surrozen, Inc. Common
stockNASDAQ
surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the wnt signaling pathway. surrozen is founded by four leading edge scientists from stanford university: k. christopher garcia, ph.d.; roel nusse, ph.d.; calvin kuo, m.d., ph.d.; and claudia janda, ph.d. each has conducted extensive research on wnt signaling, with findings that together shape surrozen's technology and approach to therapeutic development. the company is backed by the column group, a leading biotechnology venture capital firm. we are currently seeking highly creative scientists to join our founding team, and invite you to explore career opportunities on our website. if you don't find a perfect job match, but think surrozen may be the right place for you, please submit your resume to careers@surrozen.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 31.00 | 2026-11-06 | +1.94% | 0.444 |
| 1M | 23.51 | 2026-10-13 | +34.41% | 2.053 |
| 3M | 23.73 | 2026-08-13 | +33.16% | 1.426 |
| 6M | 30.14 | 2026-05-13 | +4.84% | 1.307 |
| 1Y | 12.12 | 2025-11-13 | +160.73% | 1.517 |
| 2Y | 9.20 | 2024-11-13 | +243.48% | — |
| 5Y | 142.05 | 2021-11-12 | -77.75% | 0.355 |
Surrozen, Inc. Common (NASDAQ:SRZN) stock price today is $31.60, and today's volume is 92,219. SRZN is down 0.221% today. The 30 day average volume is 422,342. SRZN market cap is $552.85M with 17.50M shares outstanding.